Hematological Biomarkers in Acute Myeloid Leukemia: A Comparative Study of New and Relapsed Iraqi Cases

Authors

  • Ghaydaa Alaa Nabat Department of Biology, College of Science, Mustansiriyah University, Baghdad, IRAQ.
  • Israa H. Hamzah
  • Bassam F. Matti

DOI:

https://doi.org/10.36320/ajb/v17.i3.19474

Keywords:

Acute myeloid leukemia , Relapse , New diagnosis ,WBC, HB .

Abstract

The hematopoietic cell cancer known as acute myeloid leukemia (AML) starts in the bone marrow and quickly spreads to the blood.   Despite recent advancements in treatment, the prognosis for people with acute myeloid leukemia (AML) remains poor . Aim: This study aims to evaluate changes in hematological parameters in Iraqi patients with acute myeloid leukemia (AML), by comparing several hematological parameters (such as white blood cell (WBC) count, hemoglobin (Hb) concentration, platelet count (PLT), and blast count) between newly diagnosed and relapsed patients, as well as a healthy control group.    Methods: The study was conducted from September 2023 to March 2024 and included 70 patients diagnosed with AML (50 new cases and 20 relapsed cases), in addition to 38 healthy individuals as a control group. Children under the age of 18, patients with AML-M3, and patients with chronic diseases or other malignancies were excluded.Peripheral blood samples were collected from all participants, and a complete blood count (CBC) was performed using automated hematology analyzers. The percentage of blast cells was assessed using Giemsa-stained blood smears, and cytological and immunological tests were performed to confirm the diagnosis. Results: The results showed significant differences between AML patients (new and relapsed) and the control group. The mean white blood cell (WBC) count in new patients was 26.69×10³/µL, and in relapsed patients, 22.05×10³/µL, compared to 7.32×10³/µL in healthy controls (P=0.0061). Hemoglobin (Hb) concentration also decreased significantly in patients, reaching 8.27 g/dL in new cases and 9.01 g/dL in relapsed cases, compared to 13.53 g/dL in controls (P≤0.0001). The platelet count (PLT) was 82.88×10³/µL in new patients and 48.39×10³/µL in relapsers, compared to 217.47×10³/µL in healthy controls (P≤0.0001). Regarding the percentage of blast cells, the study did not record significant differences between new patients (39.66% in the blood and 47.92% in the marrow) and relapsers (42.05% in the blood and 39.85% in the marrow), with P values > 0.05 in both cases   Conclusions:  The study concludes that acute myeloid leukemia (AML) causes a marked disturbance in hematologic function, leading to significant changes in hematologic parameters that can be used as supportive tools in diagnosis and clinical assessment. The results also confirm similarities in the hematologic pattern between new and relapsed cases, highlighting the importance of continuing research into immunological and molecular factors to explain this similarity and assess the likelihood of treatment response and relapse.  

Downloads

Download data is not yet available.

Author Biographies

  • Ghaydaa Alaa Nabat, Department of Biology, College of Science, Mustansiriyah University, Baghdad, IRAQ.

    Department of Biology , College of Science , Mustansiriyah University , Baghdad , Iraq 

  • Israa H. Hamzah

    Department of Biology , college of Science , Mustansiriyah University, Baghdad , Iraq 

  • Bassam F. Matti

    Hematology unit at Medical City Complex , Baghdad Medical College Teaching Hospital , Baghdad , IRAQ 

References

1. Radhi, K. A., Matti, B. F., Hamzah, I. H., & Alkasir, R. (2023). The role of miRNA-150 between different BCR-ABL p210 transcript levels and between different levels of imatinib optimal response in CML patients. Al-Mustansiriyah Journal of Science, 34(1), 16-22.‏doi.org/10.23851/mjs.v34i1.1224 DOI: https://doi.org/10.23851/mjs.v34i1.1224

2. Al-Haidary, B. A., Aziz, F. N., Al-Naiem, S. N., & MG, Y. (2008). Interleukin-1α Level among Iraqi patients with Acute Leukemia. Al-Mustansiriyah Journal of Science, 19(1).‏ https://iasj.net/iasj/download/a214837898765de5

3. Al-Mosawe, E. H. (2013). The Effect of Luteolin on Lymphocyte Cells In Leukemia Patient. Al-Mustansiriyah Journal of Science, 24(1).‏https://iasj.net/iasj/download/e0bc1eac0624b5ce

4.de Leeuw, D. C., van den Ancker, W., Denkers, F., de Menezes, R. X., Westers, T. M., Ossenkoppele, G. J., van de Loosdrecht, A. A., & Smit, L. (2013). MicroRNA profiling can classify acute leukemias of ambiguous lineage as either acute myeloid leukemia or acute lymphoid leukemia. Clinical cancer research : an official journal of the American Association for Cancer Research, 19(8), 2187–2196. doi.org/10.1158/1078-0432.CCR-12-3657 DOI: https://doi.org/10.1158/1078-0432.CCR-12-3657

5. Stevenson, F. K., Forconi, F., & Kipps, T. J. (2021). Exploring the pathways to chronic lymphocytic leukemia. Blood, The Journal of the American Society of Hematology, 138(10), 827-835.‏ doi: org/10.1182/blood.2020010029. DOI: https://doi.org/10.1182/blood.2020010029

6. Zwaan, C. M., Reinhardt, D., Hitzler, J., & Vyas, P. (2010). Acute leukemias in children with Down syndrome. Hematology/oncology clinics of North America, 24(1), 19–34. doi.org/10.1016/j.hoc.2009.11.009 DOI: https://doi.org/10.1016/j.hoc.2009.11.009

7. Short, N. J., Konopleva, M., Kadia, T. M., Borthakur, G., Ravandi, F., DiNardo, C. D., & Daver, N. (2020). Advances in the Treatment of Acute Myeloid Leukemia: New Drugs and New Challenges. Cancer discovery, 10(4), 506–525. doi.org/10.1158/2159-8290.CD-19-1011 DOI: https://doi.org/10.1158/2159-8290.CD-19-1011

8. Oudah, S. M., Hamzah, I. H., & Matti, B. F. (2024). The Role of Immune Check Point Gene Expression of Pd-1 and Tim-3 in Patients with Acute Myeloid Leukemia. Al-Mustansiriyah Journal of Science, 35(1), 27-32. doi.org/10.23851/mjs.v35i1.1418 DOI: https://doi.org/10.23851/mjs.v35i1.1418

9. Sharma, N., & Liesveld, J. L. (2023). NPM 1 Mutations in AML-The Landscape in 2023. Cancers,15(4),1177.doi.org/10.3390/cancers15041177 DOI: https://doi.org/10.3390/cancers15041177

10. Jasiem, T. M., & Al-Husseini, R. M. A. H. (2023). The role of the APE1 Asp148Glu polymorphism on the risk of acute myeloid leukemia in Iraqi patients. Baghdad Science Journal.‏ doi.org/10.21123/bsj.2023.8294 DOI: https://doi.org/10.21123/bsj.2023.8294

11. Döhner, H., Wei, A. H., Appelbaum, F. R., Craddock, C., DiNardo, C. D., Dombret, H., Ebert, B. L., Fenaux, P., Godley, L. A., Hasserjian, R. P., Larson, R. A., Levine, R. L., Miyazaki, Y., Niederwieser, D., Ossenkoppele, G., Röllig, C., Sierra, J., Stein, E. M., Tallman, M. S., Tien, H. F., … Löwenberg, B. (2022). Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN. Blood, 140(12),1345–1377. doi.org/10.1182/blood.2022016867 DOI: https://doi.org/10.1182/blood.2022016867

12. Lazarevic, V., Orsmark-Pietras, C., Lilljebjörn, H., Pettersson, L., Rissler, M., Lübking, A., ... & Fioretos, T. (2018). Isolated myelosarcoma is characterized by recurrent NFE2 mutations and concurrent preleukemic clones in the bone marrow. Blood, The Journal of the American Society of Hematology, 131(5), 577-581.‏ DOI: https://doi.org/10.1182/blood-2017-07-793620

13. Naghmi, A., & Khalid, H. (2013). Acute myeloid leukemia amongst adults.‏

14. Mozafari, R., Moeinian, M., & Asadollahi-Amin, A. (2017). Spontaneous complete remission in a patient with acute myeloid leukemia and severe sepsis. Case Reports in Hematology, 2017(1), 9593750.‏ DOI: https://doi.org/10.1155/2017/9593750

15. Abdulateef, S., Almothaffar, A., & Al-khafaji, K. R. (2017). Molecular study of FLT3-ITD mutation in Iraqi adult acute myeloid leukemia patients; Its correlation with clinicopathological parameters. Pathol Lab Med, 1, 79-82.‏

16. SPSS (2019). Statistical Packages of Social Sciences-SPSS/ IBM Statistics 26 step by step. 16th Edition. https://doi.org/10.4324/9780429056765 DOI: https://doi.org/10.4324/9780429056765

17. . Kalf, R. D., & Mamoori, Y. I. (2024). The The Role of miRNA-150 in Newly Diagnosed and Treated Patients with Acute Myeloid Leukemia. Journal of Biotechnology Research Center (JOBRC), 18(2), 112-118.‏ DOI: https://doi.org/10.24126/jobrc.2024.18.2.796

18. Mahmood, E. F., & Ahmed, A. A. (2020). Evaluation of interleukin-35 and interleukin-10 in adult acute myeloid leukemia patients before and after induction chemotherapy. Iraqi Journal of Hematology, 9(2), 82-86.‏ DOI: https://doi.org/10.4103/ijh.ijh_17_20

19. Alwan, A. F., Zedan, Z. J., & Salman, O. S. (2009). Acute myeloid leukemia: clinical features and follow-up of 115 Iraqi patients admitted to Baghdad Teaching Hospital. Tikrit Med J, 15(1), 1-8

20. Abdulateef, S., Almothaffar, A., & Al-khafaji, K. R. (2017). Molecular study of FLT3-ITD mutation in Iraqi adult acute myeloid leukemia patients; Its correlation with clinicopathological parameters. Pathol Lab Med, 1, 79-82.‏ DOI: https://doi.org/10.11648/j.ajim.20170503.11

21. Nasreldin, E., Safwat, D. M., Hamed, H. B., & Mohamed, S. A. R. (2016). T-regulatory and T-helper type17 cells associated cytokines (IL-35, IL-17) as potential diagnostic and prognostic biomarkers in egyptian acute myeloid leukemia patients. J clin cell immunol, 7(478), 2.‏ DOI: https://doi.org/10.4172/2155-9899.1000478

22. Saini, A., Kumar, M., Bhatt, S., Saini, V., & Malik, A. (2020). Cancer causes and treatments. Int. J. Pharm. Sci. Res, 11(7), 3121-3134

23. Kim, H. I., Lim, H., & Moon, A. (2018). Sex differences in cancer: epidemiology, genetics and therapy. Biomolecules & therapeutics, 26(4), 335.‏ DOI: https://doi.org/10.4062/biomolther.2018.103

24. AL-Khateeb M.J., Thair T.N., Al-bayati, A.A.H. Immune and inflammatory cytokines profile in Iraqi patients with acute and chronic myeloid leukemia. Biomedicine, (2022); 42(2): 262-267. DOI: https://doi.org/10.51248/.v42i2.1321

25. Al-Dulaimi, S. M., Al-Alwani, H. R., & Matti, B. F. (2023). Study of the hematological parameter changes of Iraqi acute myeloid leukemia patients before and after chemotherapy. J Popul Ther Clin Pharmacol, 30(12), 210-217.‏

26. Resn, N. S., & Zedan, Z. K. (2024). Impact of Chemotherapy on the hematological parameters of Acute Myeloid Leukemia Iraqi patients. Journal of Biotechnology Research Center (JOBRC), 18(2), 103-111 DOI: https://doi.org/10.24126/jobrc.2024.18.2.807

27 . Moussavi, F., Hosseini, S. N., Saket, S., & Derakhshanfar, H. (2014). The First CBC in Diagnosis of childhood acute lymphoblastic leukemia. Journal of Emergency Health Care, 3(1), 0-0.‏

28. Lyengar, V., & Shimanovsky, A. (2021). Leukemia. StatPearls.‏

29. MADLEEN, A. A., ZAINAB, A., EL-DIN, M. M. S., & TAREQ, S. A. (2018). Assessment of the serum level of interleukin-6 and interleukin-10 in newly diagnosed acute myeloid leukemia patients and the response to induction chemotherapy. The Medical Journal of Cairo University, 86(June), 1565-1572.‏ DOI: https://doi.org/10.21608/mjcu.2018.56362

30. H. A. Ahmed, A. M. Maklad, S. A. A. Khaled, and A. Elyamany, "Interleukin-27 and interleukin-35 in de novo acute myeloid leukemia: expression and significance as biological markers", J. Blood Med., pp. 341-349, 2019. https://doi.org/10.2147/JBM.S221301 DOI: https://doi.org/10.2147/JBM.S221301

31. Chang F, Shamsi TS, Waryah A. Clinical and hematological profile of acute myeloid leukemia (AML) patients of Sindh. Journal of Hematology & Thromboembolic Diseases. (2016).

32. Preethi C. Clinico-hematological study of acute myeloid leukemias. Journal of Clinical and Diagnostic Research: JCDR. (2014); 8(4): FC14.

33. Sultan S, Zaheer HA, Irfan SM, Ashar S. Demographic and clinical characteristics of adult acute Myeloid Leukemia-tertiary care experience. Asian Pacific Journal of Cancer Prevention. (2016); 17(1):357-360. DOI: https://doi.org/10.7314/APJCP.2016.17.1.357

34. Naeem R, Naeem S, Sharif A, Rafique H, Naveed A. Acute Myeloid Leukemia: Demographic Features And Frequency Of Various Subtypes In Adult Age GROUP. The Professional Medical Journal. (2017);24(09):1302-1305. DOI: https://doi.org/10.29309/TPMJ/2017.24.09.820

35. Pelcovits, A., & Niroula, R. (2020). Acute myeloid leukemia: a review. Rhode Island medical journal, 103(3), 38-40.‏

36. Dawood, S. D. (2011). Assessment of IL-6 serum level in patients with acute myeloid leukemia. Iraqi J. Cancer Med. Genet, 4, 22-28.‏ DOI: https://doi.org/10.29409/ijcmg.v4i1.51

37. Masetti, R., Vendemini, F., Zama, D., Biagi, C., Pession, A., & Locatelli, F. (2015). Acute myeloid leukemia in infants: biology and treatment. Frontiers in pediatrics, 3, 37.‏ DOI: https://doi.org/10.3389/fped.2015.00037

38. Qian, X., & Wen-jun, L. (2013). Platelet changes in acute leukemia. Cell biochemistry and biophysics, 67, 1473-1479 DOI: https://doi.org/10.1007/s12013-013-9648-y

39. Asif, N., & Hassan, K. (2013). Acute myeloid leukemia amongst adults. J Islamabad Med Dental College, 2, 58-63.‏

40. Estey, E., Hasserjian, R. P., & Döhner, H. (2022). Distinguishing AML from MDS: a fixed blast percentage may no longer be optimal. Blood, The Journal of the American Society of Hematology, 139(3), 323-332.‏ DOI: https://doi.org/10.1182/blood.2021011304

41. Thol, F., & Heuser, M. (2021). Treatment for relapsed/refractory acute myeloid leukemia. Hemasphere, 5(6), e572.‏ DOI: https://doi.org/10.1097/HS9.0000000000000572

42. Pouls, R. K., Shamoon, R. P., & Muhammed, N. S. (2012). Clinical and haematological parameters in adult AML patients: a four year experience at Nanakaly Hospital for blood diseases. Zanco Journal of Medical Sciences (Zanco J Med Sci), 16(3), 199-203.‏ DOI: https://doi.org/10.15218/zjms.2012.0035

Downloads

Published

2025-12-01

How to Cite

alaa, ghaydaa, H. Hamzah , I. ., & F. Matti , B. . (2025). Hematological Biomarkers in Acute Myeloid Leukemia: A Comparative Study of New and Relapsed Iraqi Cases. Al-Kufa University Journal for Biology, 17(3), 1-7. https://doi.org/10.36320/ajb/v17.i3.19474

Share